Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer
- 1Asha Medical
- 2MuriGenics
- 3ScellAI
Abstract
Introduction: Neutrophil reprogramming toward interferon-activated anti-tumor states represents an emerging mechanism of checkpoint sensitization; however, effective strategies to selectively induce this response in the tumor microenvironment remain elusive.
Methods: We evaluated Asha Therapy, an investigational non-invasive, low-intensity (50 kHz, 2 mT) alternating magnetic field, in triple-negative breast cancer (TNBC) cells, integrating temporal transcriptomics, global proteomics, and cytokine profiling. CITE-seq profiling of tumor tissue was used to characterize the response of neutrophils and other cell populations in the tumor microenvironment. Therapeutic efficacy of Asha Therapy alone and in combination with anti-PD1 blockade was assessed in a murine TNBC model. A 19-gene neutrophil activation signature was derived from Asha-treated tumors and projected onto three independent human TNBC cohorts (METABRIC, n=348; SCAN-B, n=874; TCGA-BRCA, n=191), with multivariable Cox models adjusted for age, tumor stage, nodal status, and TNBC subtype.
Results: Asha Therapy elicited a controlled endoplasmic reticulum (ER) stress response and adaptive unfolded-protein response in TNBC cells. This tumor-intrinsic stress matured from an acute signaling state into an immune-recruiting secretory program characterized by release of CXCL10, CCL2, and CCL20. These signals were associated with selective expansion and activation of neutrophils toward an interferon-responsive state, with additional transcriptional signatures observed within macrophage, T cell, and cancer-associated fibroblast populations. In the murine TNBC model, Asha monotherapy showed directional anti-metastatic effects, while combination with anti-PD1 blockade achieved significant therapeutic benefit, reducing lung metastasis and mortality by 88% (HR=0.12, p<0.05) without overt cytotoxicity. Projection of the 19-gene neutrophil activation signature onto the three human TNBC cohorts revealed significant association with improved overall survival (pooled HR=0.71, 95% CI: 0.60–0.83, p=0.01).
Discussion: These findings indicate neutrophil reprogramming as a key feature of the low-intensity EMF therapeutic response. These preclinical findings support further investigation of Asha Therapy as a candidate non-pharmacologic strategy to activate innate immunity and improve responsiveness to checkpoint blockade in poorly immunogenic tumors.
Related
- Immune checkpoint blockade activates macrophages and remodels the lymph node microenvironment in melanoma metastasis
- 427 Eomes sustains progenitor exhausted CD8 T-cell differentiation required for optimal response to immune checkpoint blockade in melanoma
- Novel retinoic acid receptor-related orphan receptor gamma inverse agonist enhances checkpoint blockade in hepatocellular carcinoma: a preclinical mouse study
- CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade.
- Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade
BibTeX
@article{sharma2026noninvasive,
title = {{Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer}},
author = {Vivek Sharma and Chandra Khantwal and Kishori Konwar},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1861048},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1861048/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Non-invasive electromagnetic fields induce anti-tumor neutrophil reprogramming and enhance checkpoint blockade in breast cancer
AU - Vivek Sharma
AU - Chandra Khantwal
AU - Kishori Konwar
PY - 2026
DA - 2026/10/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1861048
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1861048/full
AB - Introduction: Neutrophil reprogramming toward interferon-activated anti-tumor states represents an emerging mechanism of checkpoint sensitization; however, effective strategies to selectively induce this response in the tumor microenvironment remain elusive. Methods: We evaluated Asha Therapy, an investigational non-invasive, low-intensity (50 kHz, 2 mT) alternating magnetic field, in triple-negative breast cancer (TNBC) cells, integrating temporal transcriptomics, global proteomics, and cytokine profiling. CITE-seq profiling of tumor tissue was used to characterize the response of neutrophils and other cell populations in the tumor microenvironment. Therapeutic efficacy of Asha Therapy alone and in combination with anti-PD1 blockade was assessed in a murine TNBC model. A 19-gene neutrophil activation signature was derived from Asha-treated tumors and projected onto three independent human TNBC cohorts (METABRIC, n=348; SCAN-B, n=874; TCGA-BRCA, n=191), with multivariable Cox models adjusted for age, tumor stage, nodal status, and TNBC subtype. Results: Asha Therapy elicited a controlled endoplasmic reticulum (ER) stress response and adaptive unfolded-protein response in TNBC cells. This tumor-intrinsic stress matured from an acute signaling state into an immune-recruiting secretory program characterized by release of CXCL10, CCL2, and CCL20. These signals were associated with selective expansion and activation of neutrophils toward an interferon-responsive state, with additional transcriptional signatures observed within macrophage, T cell, and cancer-associated fibroblast populations. In the murine TNBC model, Asha monotherapy showed directional anti-metastatic effects, while combination with anti-PD1 blockade achieved significant therapeutic benefit, reducing lung metastasis and mortality by 88% (HR=0.12, p<0.05) without overt cytotoxicity. Projection of the 19-gene neutrophil activation signature onto the three human TNBC cohorts revealed significant association with improved overall survival (pooled HR=0.71, 95% CI: 0.60–0.83, p=0.01). Discussion: These findings indicate neutrophil reprogramming as a key feature of the low-intensity EMF therapeutic response. These preclinical findings support further investigation of Asha Therapy as a candidate non-pharmacologic strategy to activate innate immunity and improve responsiveness to checkpoint blockade in poorly immunogenic tumors.
SN - 1664-3224
ER -